Prophylactic and therapeutic anticoagulation for thrombosis - Major issues in oncology

Nature Clinical Practice Oncology

Volumn 6, Issue 2, 2009, Pages 74-84

  Carrier, Marc ^a   Lee, Agnes Y Y ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; CERTOPARIN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RIVAROXABAN; THALIDOMIDE; TINZAPARIN; WARFARIN;

ABDOMINAL SURGERY; ANTICOAGULATION; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPRESSION GARMENT; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLIOMA; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NEUROSURGERY; ONCOLOGY; OUTPATIENT CARE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; BREAST CANCER; BREAST SURGERY; COLORECTAL SURGERY; CRANIOTOMY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL RESEARCH; OPTIMAL DRUG DOSE; PATIENT MONITORING; RISK BENEFIT ANALYSIS; THROMBOSIS PREVENTION;

ANTICOAGULANTS; HEALTH PLANNING GUIDELINES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOSIS; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM;

EID: 73949161096     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1244     Document Type: Review

References (80)

1. Khorana AA et al. (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5: 632-634
2. Blom JW et al. (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715-722
3. Hutten BA et al. (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18: 3078-3083
4. Prandoni P et al. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484-3488
5. Elting LS et al. (2004) Outcomes and costs of deep venous thrombosis among patients with cancer. Arch Intern Med 164: 1653-1661
6. Geerts WH et al. (2004) Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S-400S
7. Leonardi MJ et al. (2007) A systematic review of deep venous thrombosis prophylaxis in cancer patients: Implications for improving quality. Ann Surg Oncol 14: 929-936
8. Fricker JP et al. (1988) Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 18: 561-567
9. McLeod RS et al. (2001) Subcutaneous heparin versus low molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: Results of the Canadian colorectal DVT prophylaxis trial: A randomized, double-blind trial. Ann Surg 233: 438-444
10. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 84 1099-1103
11. Petrov M et al. (2007) Enoxaparin versus heparin prophylaxis for venous thromboembolism after abdominal oncologic surgery: A randomized double-blind controlled trial [abstract #668]. J Thromb Haemost 5: 668
12. Bergqvist D et al. (2005) Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 units in 2070 patients. Br J Surg 82: 496-501
13. Balibrea JL et al. (2007) Bemiparin Cooperative Study Group in Surgery for Cancer. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: An audit of practice. Int J Surg 5: 114-119
14. Simonneau G et al. (2006) A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 4: 1693-1700
15. Bergqvist D et al. (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975-980
16. Lausen I et al. (1998) Incidence and prevention of deep venous thrombosis occurring late after general surgery: Randomized controlled study of prolonged thromboprophylaxis. Eur J Surg 164: 657-663
17. Rasmussen MS et al. (2003) Prolonged prophylaxis with low molecular weight heparin (Dalteparin) following major abdominal surgery for malignancy. Blood 102: 56a
18. Agnelli G et al. (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The ®ISTOS project. Ann Surg 243: 89-95
19. Agnelli G et al. (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 1212-1220
20. Lyman GH et al. (2007) American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 1-16
21. Marras LC et al. (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer 89: 640-646
22. Simanek R et al. (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro-Oncology 9: 89-95
23. Semrad TJ et al. (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106: 601-608
24. Cerrato D et al. (1978) Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 49: 378-381
25. Melon E et al. (1987) Deep venous thrombosis prophylaxis by low molecular weight heparin in neurosurgical patients. Anesthesiology 75: A214
26. Nurmohamed MT et al. (1996) Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 75: 233-238
27. Agnelli G et al. (1998) Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339 80-85
28. Iorio A and Agnelli G (2000) Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: A meta-analysis. Arch Int Med 160: 2327-2332
29. Dickinson LD et al. (1998) Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 43: 1074-1081
30. Goldhaber SZ et al. (2002) Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122: 1933-1937
31. MacDonald RL et al. (2003) Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurology 59: 363-372
32. Perry JR et al. (2007) PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma [abstract#2011]. J Clin Oncol 25 (suppl): 77s
33. Clarke-Pearson DL et al. (1983) Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of low-dose heparin. Am J Obst Gynecol 145: 606-613
34. Clarke-Pearson DL et al. (1990) A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obst Gynecol 75: 684-689
35. Einstein MH et al. (2007) Venous thromboembolism prevention in gynecologic cancer surgery: A systematic review. Gynecol Onc 105: 813-819
36. Borstad E et al. (1988) Comparison of low molecular weight heparin vs unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 67: 99-103
37. Kaaja R et al. (1992) Comparison of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol 47: 141-145
38. von Tempelhoff GF et al. (2000) Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 16: 815-824
39. Baykal et al. (2001) Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: A randomised prospective double-blind clinical study. Eur J Gynaecol Onc 22: 127-130
40. Cade JF et al. (1983) Prophylaxis of venous thrombosis after major thoracic surgery. ANZ J Surg 53: 301-304
41. Azorin JF et al. (1997) Efficacy and tolerability of fraxiparine in the prevention of thromboembolic complications in oncologic thoracic surgery. Ann Cardiol Angeiol (Paris) 46: 341-347
42. Bigg SW et al. (1992) Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology 39: 309-313
43. Sawczuk IS et al. (2002) Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery. Cancer Invest 20: 889-892
44. Patiar S et al. (2007) Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg 94: 412-420
45. Lin PP et al. (1998) Deep venous thrombosis after orthopedic surgery in adult cancer patients. J Surg Onc 68: 41-47
46. Clarke-Pearson DL et al. (1984) Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 63: 92-98
47. Turpie AG et al. (1977) Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 27: 435-438
48. Stein PD et al. (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 1999: 60-68
49. Khorana AA et al. (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24: 484-490
50. Levine M et al. (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343: 886-889
51. Ciftci A et al. (2007) Thrombosis in patients with lung cancer and the effectiveness of low warfarin prophylaxis on patients survival [abstract #563]. J Thromb Haemost 5 (suppl1): 563
52. Haas SK et al. (2005) Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC Studies [abstract #OR059]. J Thromb Haemost 3 (Suppl 1): OR059
53. Pelzer H et al. (2007) Prospective, randomized open trial of enoxaparin in patient with advanced pancreatic cancer undergoing first-line chemotherapy [abstract #PT488]. J Thromb Haemost 5 (Suppl 2): PT488
54. Hirsh J (2007) Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 131: 275-277
55. Amin A et al. (2007) Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 5: 1610-1616
56. Kucher et al. (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 352 969-971
57. Francis CW (2007) Prophylaxis for thromboembolism in hospitalized medical patients. N Engl Med 356: 1438-1444
58. Van Dongen CJ et al.: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001100. doi:10.1002/ 14651858.CD001100.pub2
59. Lee AYY (2003) Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol 128: 291-302
60. Ageno W et al. (2002) Selecting patients for home treatment of deep vein thrombosis: The problem of cancer. Haematologica 87 286-291
61. Martel N et al. (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710-2715
62. Lee AYY et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153
63. Hull RD et al. (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119: 1062-1072
64. Meyer G et al. (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Int Med 162: 1729-1735
65. Deitcher SR et al. (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Applied Thromb Hemost 12: 389-396
66. The van Gogh Investigators (2007) Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357: 1094-1104
67. The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism Circulation 112: 416-422
68. Buller HR et al. (2204) Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 suppl): 401S-428S
69. Goerner A (1931) The influence of anticlotting agents on transplantation growth of tumor tissue. J Lab Clin Med 16: 369-372
70. Lebeau B et al. (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74: 38-45
71. Elias EG et al. (1975) Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 36: 129-136
72. Zacharski LR et al. (1981) Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245: 831-835
73. Chahinian AP et al. (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7 993-1002
74. Altinbas M et al. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266-1271
75. Klerk CPW et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135
76. Kakkar AK et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944-1948
77. Sideras K et al. (2006) Low-molecular-weight-heparin in patients with advanced cancer: A phase 3 clinical trial. Mayo Clin Proc 81: 758-767
78. Zacharski LR et al. (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer 53: 2046-2052
79. Maurer LH et al. (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study. J Clin Oncol 15: 3378-3387
80. Lazo-Langner A et al. (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5: 729-737